All In Biotech

Drug Trial Radar · NCT03852719

Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis Delta

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Apr 17, 2019

Primary completion

Nov 26, 2020

Study completion Aug 8, 2024

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Feb 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of bulevirtide administered subcutaneously (SC) for 48 weeks at a dose of 2 mg or 10 mg once daily for treatment of chronic hepatitis delta (CHD) in comparison to delayed treatment. The main goal of this study is to determine the effectiveness of bulevirtide in participants randomized to bulevirtide 2 mg or 10 mg once daily SC as compared to participants randomized to delayed treatment for 48 weeks. Treatment will continue through Week 144 (participants randomized to delayed treatment will change to bulevirtide 10 mg once daily SC after Week 48 through Week 144). All participants will be followed off-treatment for an additional 96 weeks.

Conditions

  • Chronic Hepatitis Delta

Interventions

  • BulevirtideDrug

    Administered via SC injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Combined Response at Week 48Time frame: Week 48

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • New York University School of Medicine, an administrative unit of New York University, an education corporation

    New York, New York

  • Cornell University Well Madical College

    New York, New York

  • Universitätsklinikum Essen (AoR), Klinik für Gastroenterologie und Hepatologie

    Essen, Germany

  • Universitätsklinikum Frankfurt Medizinische Klinik 1

    Frankfurt am Main, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie

    Hanover, Germany

  • Heidelberg University Hospital, Departament of Gastroenterology, Infectious Diseases, Intoxication

    Heidelberg, Germany

  • Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Università di Modena e Reggio Emilia- Ospedale Civile S.

    Modena, Italy

  • U.O. Epatologia - Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy

  • State Budgetary Educational Institution of Higher Professional Education "South Ural State Medical University" of the Ministry of Healthcare of the Russian Federation

    Chelyabinsk, Russia

  • Specialized clinical Infectious diseases Hospital

    Krasnodar, Russia

  • Federal Budget Institution of Science "Central Research Institute of Epidemiology" of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance

    Moscow, Russia

  • Federal State Budgetary Institution National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation

    Moscow, Russia

  • LLC"Clinic of Modern Medicine"

    Moscow, Russia

  • Moscow Regional Scientific and Research Clinical Institute

    Moscow, Russia

  • LLC Medical Company "Hepatolog"

    Samara, Russia

  • Stavropol Regional Hospital

    Stavropol, Russia

  • Karolinska University Hospital Huddinge, Dept of Infectious Diseases

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.